Portola Pharmaceuticals Inc.
270 E. Grand Avenue
South San Francisco , CA 94080
USA
Phone: (650) 246-7000
Fax: (650) 246-7376
[email protected]
Visit Website

Related Content

FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process
News | Antiplatelet and Anticoagulation Therapies
FDA Approves Portola Pharmaceuticals' Prior Approval Supplement for Andexxa Generation 2 Manufacturing Process

January 2, 2019 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval ...

Home January 02, 2019
arrow
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Feature | Antiplatelet and Anticoagulation Therapies
FDA Clears First Reversal Agent for Rivaroxaban, Apixaban Anticoagulants

May 7, 2018 — The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first ...

Home May 07, 2018
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now